Home
Mercati
Grafici & Idee
Algo
Notizie
Store
Broker
Scarica
Calendario Economico
Segnali di Trading
Terminale Web
Digita
/
per cercare: @user, $symbol
Cerca
Accedi
Crea un account
Italiano
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Türkçe
ACIU
#6082
AC Immune SA
2.9
3
-0.34%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
Intervallo Annuale
Variazione giornaliera
-0.34%
Variazione Mensile
-17.93%
Variazione di 6 mesi
+42.23%
Variazione Annuale
+14.45%
Chiusura Precedente
2.9
4
Open
2.9
3
Bid
Ask
Low
2.9
3
High
2.9
3
Volume
17
Mercati
Mercato Azionario Statunitense
Salute
ACIU
Open full chart
Financials
Overview
Estratto Conto
Statistics
Dividends
Quarterly
Annual
Value
Q4, 24
TTM
Key stats
Total common shares outstanding
100.41 M
366.71 M
Valuation ratios
Enterprise value
271.11 M
1.33 B
Price to earnings ratio
—
—
Price to sales ratio
—
—
Price to cash flow ratio
—
—
Price to book ratio
—
—
Enterprise value to EBITDA ratio
—
—
Profitability ratios
Return on assets %
—
—
Return on equity %
—
—
Return on invested capital %
—
—
Gross margin %
—
—
Operating margin %
—
—
EBITDA margin %
—
—
Net margin %
—
—
Liquidity ratios
Quick ratio
—
—
Current ratio
—
—
Inventory turnover
—
—
Asset turnover
—
—
Solvency ratios
Debt to assets ratio
—
—
Debt to equity ratio
—
—
Long term debt to total assets ratio
—
—
Long term debt to total equity ratio
—
—
Per share metrics
Operating cash flow per share
—
—
EBIT per share
—
—
EBITDA per share
—
—
Total debt per share
—
—
Cash per share
—
—
Net current asset value per share
—
—
Tangible book value per share
—
—
Working capital per share
—
—
Book value per share
—
—
Notizie
AC Immune avvia trial di fase 1 su inibitore NLRP3 cerebrale
AC Immune begins phase 1 trial of brain-penetrant NLRP3 inhibitor
2026 Market Outlook: Focus On Pharma For Consistent Returns, Potential Skyrocketing Shares
AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD
Tesla and Rivian among market cap stock movers on Friday
AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's - AC Immune (NASDAQ:ACIU)
AC Immune stock rises after positive Parkinson’s disease trial data
Il trattamento per il Parkinson di AC Immune mostra risultati promettenti nel rallentare la malattia
AC Immune’s Parkinson’s treatment shows promise in slowing disease
AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates
Alector (ALEC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline